Omega-3 polyunsaturated fatty acids ameliorate ethanol-induced adipose hyperlipolysis: A mechanism for hepatoprotective effect against alcoholic liver disease

Biochim Biophys Acta Mol Basis Dis. 2017 Dec;1863(12):3190-3201. doi: 10.1016/j.bbadis.2017.08.026. Epub 2017 Aug 25.

Abstract

Alcohol exposure induces adipose hyperlipolysis and causes excess fatty acid influx into the liver, leading to alcoholic steatosis. The impacts of omega-3 polyunsaturated fatty acids (n-3 PUFA) on ethanol-induced fatty liver are well documented. However, the role of n-3 PUFA in ethanol-induced adipose lipolysis has not been sufficiently addressed. In this study, the fat-1 transgenic mice that synthesizes endogenous n-3 from n-6 PUFA and their wild type littermates with an exogenous n-3 PUFA enriched diet were subjected to a chronic ethanol feeding plus a single binge as model to induce liver injury with adipose lipolysis. Additionally, the differentiated adipocytes from 3T3-L1 cells were treated with docosahexaenoic acid or eicosapentaenoic acid for mechanism studies. Our results demonstrated that endogenous and exogenous n-3 PUFA enrichment ameliorates ethanol-stimulated adipose lipolysis by increasing PDE3B activity and reducing cAMP accumulation in adipocyte, which was associated with activation of GPR120 and regulation of Ca2+/CaMKKβ/AMPK signaling, resultantly blocking fatty acid trafficking from adipose tissue to the liver, which contributing to ameliorating ethanol-induced adipose dysfunction and liver injury. Our findings identify that endogenous and exogenous n-3 PUFA enrichment ameliorated alcoholic liver injury by activation of GPR120 to suppress ethanol-stimulated adipose lipolysis, which provides the new insight to the hepatoprotective effect of n-3 PUFA against alcoholic liver disease.

Keywords: Adipose lipolysis; Alcoholic liver disease; CaMKKβ; GPR120; Omega-3 polyunsaturated fatty acids.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 3T3-L1 Cells
  • AMP-Activated Protein Kinase Kinases
  • Adipocytes / drug effects
  • Adipocytes / metabolism
  • Adipocytes / pathology
  • Adipose Tissue / drug effects
  • Adipose Tissue / metabolism
  • Adipose Tissue / pathology
  • Adiposity / drug effects*
  • Animals
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase / metabolism
  • Cyclic AMP / metabolism
  • Cyclic Nucleotide Phosphodiesterases, Type 3 / metabolism
  • Docosahexaenoic Acids / pharmacology
  • Eicosapentaenoic Acid / pharmacology
  • Ethanol / pharmacology*
  • Fatty Acids, Omega-3 / pharmacology*
  • Fatty Liver, Alcoholic / prevention & control
  • Female
  • Lipolysis / drug effects
  • Liver Diseases, Alcoholic / metabolism
  • Liver Diseases, Alcoholic / prevention & control*
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Protective Agents / pharmacology*
  • Protein Kinases / metabolism
  • Receptors, G-Protein-Coupled / metabolism
  • Signal Transduction

Substances

  • FFAR4 protein, mouse
  • Fatty Acids, Omega-3
  • Protective Agents
  • Receptors, G-Protein-Coupled
  • Docosahexaenoic Acids
  • Ethanol
  • Eicosapentaenoic Acid
  • Cyclic AMP
  • Protein Kinases
  • Calcium-Calmodulin-Dependent Protein Kinase Kinase
  • AMP-Activated Protein Kinase Kinases
  • Cyclic Nucleotide Phosphodiesterases, Type 3
  • Pde3b protein, mouse